A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.

NCT ID: NCT07176728

Last Updated: 2026-01-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-22
• Study Completion Date: 2026-01-30

Brief Summary

This study is designed to evaluate a new investigational drug, BAY 3389934, in healthy Japanese volunteers. The primary purpose is to see how safe the drug is and how well it is tolerated by the body when given at different doses. BAY 3389934 is being developed for the potential treatment of a serious blood clotting condition called sepsis-associated disseminated intravascular coagulation (DIC). The research will be conducted as a single-blind, placebo-controlled, dose-escalation study. This means that participants will be randomly assigned to receive either the active drug (BAY 3389934) or a placebo (an inactive substance), and they will not know which one they are receiving. The study will involve up to 16 healthy male and female Japanese participants, aged between 18 and 55. The study consists of two parts, called dose steps. In the first step, participants will receive a single 4-hour intravenous (IV) infusion of BAY 3389934 at a dose of 15 mg/h, or a placebo. Based on the safety and tolerability results from this first step, a second, higher dose will be selected for the next group of participants in the second step. Throughout the study, researchers will closely monitor participants for any side effects (adverse events). They will also collect blood and urine samples to study how the drug is absorbed, distributed, and eliminated by the body (pharmacokinetics or PK) and what effects it has on the body's clotting system (pharmacodynamics or PD). This involves measuring specific substances in the blood, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT). Participants will stay at the study center for 4 days and will have a follow-up visit 3 to 5 days after they are discharged. The information gathered from this study is crucial for the future clinical development of BAY 3389934 in Japan and for designing future studies in patients with septic DIC.

Conditions

Sepsis Associated Disseminated Intravascular Coagulation (DIC)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Dose Step 1 BAY 3389934

15 mg/h/ intravenous Single Dose for 4 h fasting

Group Type: EXPERIMENTAL

BAY 3389934

Intervention Type: DRUG

Solution for intravenous infusion

Dose Step 2 BAY 3389934

Max. dose 35 mg / h / intravenous - actual dose will be determined after Dose Step 1 Single Dose for 4 h fasting

Group Type: EXPERIMENTAL

BAY 3389934

Intervention Type: DRUG

Solution for intravenous infusion

Dose Step 1 and Dose Step 2 Placebo

Placebo / intravenous Single Dose for 4 h Fasting

Group Type: PLACEBO_COMPARATOR

Matching Placebo / Diluent

Intervention Type: DRUG

Solution for intravenous infusion

Interventions

BAY 3389934

Solution for intravenous infusion

Intervention Type: DRUG

Matching Placebo / Diluent

Solution for intravenous infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant must be 18 to 55 years of age inclusive.

• Participants who are overtly healthy Japanese as determined by medical evaluation.
• Body mass index (BMI) within the range 18 - 29.9 kg/m² (inclusive).
• Male participants must agree to use specified contraception during the study and for at least 90 days plus 5 half-lives after.
• Female participants must be a Woman of Nonchildbearing Potential (WONCBP).
• Capable of giving signed informed consent.
• Willing to comply with the requirements and restrictions listed in the protocol.

Exclusion Criteria

• Any medical disorder, condition, or history that would impair participation.

• Known hypersensitivity to the study drug or its excipients.
• Known disorders with increased bleeding risk or known congenital/acquired coagulation disorders.
• Use of prescription drugs, over-the-counter drugs, or herbal products within 14 days or 5 half-lives before the study.
• Clinically relevant findings in the ECG, such as a QTcF over 450 msec.
• Systolic blood pressure below 90 mmHg or above 140 mmHg at screening and admission.
• Diastolic blood pressure below 40 mmHg or above 90 mmHg at screening and admission.
• Positive results for Hepatitis B, Hepatitis C, or HIV.
• Positive drug screening, alcohol breath test, or urine cotinine test.
• Clinically relevant deviations of the screened laboratory parameters from reference ranges at the screening visit.
• Positive pregnancy test.
• Donation of blood or plasma within specified timeframes before the study.
• Lack of compliance with lifestyle restrictions (e.g., alcohol, specific foods, strenuous activity).
• Previous participation in this or another clinical study within a specified timeframe.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bayer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

SOUSEIKAI Fukuoka Mirai Hospital

Fukuoka, Fukuoka Pref, Japan

Site Status: RECRUITING

SOUSEIKAI Fukuoka Mirai Hospital

Fukuoka, , Japan

Site Status: RECRUITING

Countries

Japan

Central Contacts

Bayer Clinical Trials Contact

Role: CONTACT

clinical-trials-contact@bayer.com

(+)1-888-84 22937

Facility Contacts

Shunji Matsuki

Role: primary

Other Identifiers

22371

Identifier Type: -

Identifier Source: org_study_id